沃森生物：冻干带状疱疹病毒mRNA疫苗获药物临床试验批准

Core Viewpoint - Watson Bio (300142.SZ) announced that its subsidiary, Beijing Watson Innovation Biotechnology Co., Ltd., along with Yunnan Vaccine Laboratory Co., Ltd. and Yuxi Watson Biotechnology Co., Ltd., has jointly developed and applied for clinical trials of a lyophilized varicella-zoster virus mRNA vaccine in collaboration with Fudan University and Shanghai Blue Magpie Biopharmaceutical Co., Ltd. The vaccine has recently received the Clinical Trial Approval Notification from the National Medical Products Administration, allowing the commencement of clinical trials aimed at preventing shingles [1]. Group 1 - Watson Bio's subsidiary has received approval for clinical trials of a new mRNA vaccine targeting shingles [1] - The vaccine development involves collaboration with notable institutions including Fudan University and Shanghai Blue Magpie Biopharmaceutical Co., Ltd. [1] - The approval indicates that the vaccine meets the necessary requirements for drug registration as of September 18, 2025 [1]